BRPI0509366B8 - composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica - Google Patents

composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica

Info

Publication number
BRPI0509366B8
BRPI0509366B8 BRPI0509366A BRPI0509366A BRPI0509366B8 BR PI0509366 B8 BRPI0509366 B8 BR PI0509366B8 BR PI0509366 A BRPI0509366 A BR PI0509366A BR PI0509366 A BRPI0509366 A BR PI0509366A BR PI0509366 B8 BRPI0509366 B8 BR PI0509366B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical
methods
pharmaceutical composition
compositions
hyperkalemia
Prior art date
Application number
BRPI0509366A
Other languages
English (en)
Inventor
Charmot Dominique
Liu Futian
Klaerner Gerrit
Ting Chang Han
James Cope Michael
Liu Mingjun
Kwok-Kong Mong Tony
Original Assignee
Ilypsa Inc
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35054544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509366(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/814,749 external-priority patent/US8192758B2/en
Priority claimed from US10/814,527 external-priority patent/US7854924B2/en
Priority claimed from US10/813,872 external-priority patent/US8282960B2/en
Application filed by Ilypsa Inc, Relypsa Inc filed Critical Ilypsa Inc
Publication of BRPI0509366A publication Critical patent/BRPI0509366A/pt
Publication of BRPI0509366B1 publication Critical patent/BRPI0509366B1/pt
Publication of BRPI0509366B8 publication Critical patent/BRPI0509366B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
    • C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"método para remover potássio de um indivíduo animal, formulação farmacêutica, métodos para tratar uma doença e para determinar uma permeabilidade de casca a um íon, composição farmacêutica, composição de núcleo-casca, e, método para sintetizar um polímero de alfa-fluoroacrilato". a presente invenção provê métodos e composições para o tratamento de desequilíbrios iônicos. em particular, a invenção provê composições, que compreendem polímeros de ligação de potássio e composições farmacêuticas dos mesmos. métodos de uso das composições poliméricas e farmacêuticas para benefícios terapêuticos e/ ou profiláticos são expostos nesta. exemplos destes métodos incluem o tratamento de hipercalemia, tal que hipercalemia causada por falha renal e/i ou o uso de drogas que causam hipercalemia.
BRPI0509366A 2004-03-30 2005-03-30 composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica BRPI0509366B8 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10/814,749 2004-03-30
US10/813,872 2004-03-30
US10/814,749 US8192758B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/814,527 2004-03-30
US10/814,527 US7854924B2 (en) 2004-03-30 2004-03-30 Methods and compositions for treatment of ion imbalances
US10/813,872 US8282960B2 (en) 2004-03-30 2004-03-30 Ion binding compositions
US10/965,274 US7488495B2 (en) 2004-03-30 2004-10-13 Ion binding polymers and uses thereof
US10/965,274 2004-10-13
PCT/US2005/010978 WO2005097081A1 (en) 2004-03-30 2005-03-30 Ion binding polymers and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0509366A BRPI0509366A (pt) 2007-09-04
BRPI0509366B1 BRPI0509366B1 (pt) 2018-07-24
BRPI0509366B8 true BRPI0509366B8 (pt) 2021-05-25

Family

ID=35054544

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0509365A BRPI0509365B8 (pt) 2004-03-30 2005-03-30 composição farmacêutica, kit farmacêutico, e, uso da referida composição
BRPI0509366A BRPI0509366B8 (pt) 2004-03-30 2005-03-30 composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica
BRPI0509331A BRPI0509331B8 (pt) 2004-03-30 2005-03-30 uso de uma composição de ligação de sódio

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0509365A BRPI0509365B8 (pt) 2004-03-30 2005-03-30 composição farmacêutica, kit farmacêutico, e, uso da referida composição

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0509331A BRPI0509331B8 (pt) 2004-03-30 2005-03-30 uso de uma composição de ligação de sódio

Country Status (12)

Country Link
US (14) US7776319B2 (pt)
EP (3) EP1732524B1 (pt)
JP (3) JP4964122B2 (pt)
KR (3) KR101228233B1 (pt)
AU (3) AU2005231424B2 (pt)
BR (3) BRPI0509365B8 (pt)
CA (3) CA2557848C (pt)
DE (1) DE112005000730B4 (pt)
GB (3) GB2430367B (pt)
MX (1) MXPA06011270A (pt)
PL (1) PL1732523T3 (pt)
WO (3) WO2005097081A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660104B1 (en) 2003-08-26 2010-03-10 Shire Holdings AG Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
ES2453048T3 (es) * 2004-03-30 2014-04-03 Relypsa, Inc. Polímeros de unión de ión y usos de los mismos
BRPI0509365B8 (pt) * 2004-03-30 2021-05-25 Ilypsa Inc composição farmacêutica, kit farmacêutico, e, uso da referida composição
WO2007041569A1 (en) * 2005-09-30 2007-04-12 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
BRPI0616603A2 (pt) * 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
WO2007038801A2 (en) * 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
JP5484059B2 (ja) * 2006-10-06 2014-05-07 エスシーアイエル テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 脊髄核インプラント
TW200835508A (en) * 2006-12-26 2008-09-01 Otsuka Pharma Co Ltd Sodium uptake inhibitor, potassium uptake inhibitor, phosphorus uptake inhobitor, and prophylactic agent, therapeutic agent and food including the said inhibitors
WO2008078795A1 (ja) * 2006-12-26 2008-07-03 Chisso Corporation 架橋セルロース誘導体の金属塩
EP2671584A3 (en) * 2007-05-04 2014-03-26 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
AU2008292907A1 (en) * 2007-08-29 2009-03-05 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
JP5294681B2 (ja) * 2008-04-28 2013-09-18 東京エレクトロン株式会社 基板処理装置及びその基板搬送方法
US8337824B2 (en) * 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
AU2013204879B2 (en) * 2008-08-22 2015-10-29 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
PT2365988E (pt) * 2008-08-22 2015-10-22 Relypsa Inc Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US20120107381A1 (en) * 2009-05-13 2012-05-03 Relypsa, Inc. Powder formulations of potassium-binding active agents
KR101839038B1 (ko) 2010-03-20 2018-03-16 리립사, 인크. 폴리플루오로아크릴레이트 입자를 제조하기 위한 연속식 방법
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
SI2673237T2 (sl) 2011-02-11 2025-12-31 Zs Pharma, Inc Uporaba cirkonijevega silikata v zdravljenju hiperkalemije
RU2619108C2 (ru) 2011-06-27 2017-05-12 Релипса, Инк. Фторирование эфиров акриловой кислоты и их производных
ES2895909T3 (es) 2011-06-27 2022-02-23 Vifor Pharma Tech Ltd Procedimiento para la conversión de un éster polimérico a un ácido polimérico
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
CN104968336A (zh) * 2012-07-11 2015-10-07 Zs制药公司 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物
CA2879425A1 (en) * 2012-07-19 2014-01-23 Relypsa, Inc. Compositions comprising crosslinked cation-binding polymers
WO2014023826A1 (en) 2012-08-09 2014-02-13 Dsm Ip Assets B.V. Process for drying polymeric materials
KR20210005314A (ko) * 2012-10-08 2021-01-13 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제
CN104797263B (zh) 2012-10-22 2018-02-09 Zs制药公司 用于治疗高钾血症的微孔硅酸锆
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
EP3081939B1 (en) * 2013-12-11 2021-02-17 Kagami Inc. Marker for early diagnosis of kidney failure
US9675636B2 (en) * 2014-01-31 2017-06-13 University Of Kansas Micelle sequestering polymers
JP6468780B2 (ja) * 2014-09-30 2019-02-13 積水化成品工業株式会社 中空樹脂粒子及びその製造方法
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
EP3236940B1 (en) * 2014-12-23 2020-02-05 Ardelyx, Inc. Compositions and methods for treating hyperkalemia
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
JP2018125951A (ja) * 2017-01-31 2018-08-09 日本電産株式会社 モータ及びそれを備えた送風装置
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
JP7365631B2 (ja) * 2019-09-02 2023-10-20 国立大学法人福井大学 ホスホン酸又はホスホン酸エステル構造を有するコア－シェル型高分子微粒子、粒子分散液、成形体及び前記微粒子の製造方法
CN113244339B (zh) * 2021-06-04 2021-09-24 南京厚生药业有限公司 一种用于高脂血症的考来烯胺散及其制备方法
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
WO2024035944A1 (en) * 2022-08-12 2024-02-15 University Of Kansas Extraction of critical minerals using polyanions

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2340111A (en) * 1942-07-03 1944-01-25 Gen Electric Process for removing cations from liquid media
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
FR2171934B1 (pt) 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
US4191812A (en) * 1978-09-19 1980-03-04 Rohm And Haas Company Ion exchange process involving emulsion ion exchange resins
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
DE3031737A1 (de) 1980-08-22 1982-04-01 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von perlpolymerisaten einheitlicher teilchengroesse
DE3149136A1 (de) 1981-12-11 1983-06-23 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US5238924A (en) * 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
KR920006865B1 (ko) 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 입자나 액적을 피복하는 방법과 장치
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) * 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
FR2634377B1 (fr) 1988-06-30 1991-09-27 Cortial Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
DK0563731T3 (da) * 1992-03-28 1996-03-18 Hoechst Ag Lægemidler indeholdende polyhydromethylenderivater, fremgangsmåde til deres fremstilling og deres anvendelse
ATE168707T1 (de) * 1992-08-20 1998-08-15 Du Pont Vernetzte polymerische ammoniumsalze
AU6818894A (en) 1993-05-20 1994-12-20 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995014531A1 (en) 1993-11-25 1995-06-01 Salternate B.V. Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
EP1014941B2 (en) 1996-06-26 2017-05-17 The Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
CA2258744A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
CA2315088A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
KR100440544B1 (ko) * 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
HK1040056A1 (zh) * 1998-11-06 2002-05-24 G.D. Searle & Co. 血管紧张肽转换酶抑制剂及醛甾䣳对抗物的综合治疗以减低心血管疾病的发病率及死亡率
EP1140037A1 (en) * 1999-01-07 2001-10-10 ELAN CORPORATION, Plc Multiparticulate oral dosage forms
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
CA2396915A1 (en) 2000-01-14 2001-07-19 Otsuka Pharmaceutical Factory, Inc. Sodium ion absorption inhibitors, and preventive and therapeutic agents and foods containing the same
FR2812632B1 (fr) 2000-08-07 2003-03-07 Solvay Procede pour la synthese de composes fluoroorganiques
AU2002232955A1 (en) 2000-11-20 2002-05-27 Dow Global Technologies Inc. In vivo use of water absorbent polymers
AU2002242103A1 (en) 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
JP2004149525A (ja) 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
CA2516457C (en) * 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
CA2551528A1 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
BRPI0509365B8 (pt) * 2004-03-30 2021-05-25 Ilypsa Inc composição farmacêutica, kit farmacêutico, e, uso da referida composição
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) * 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
BRPI0616603A2 (pt) * 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
WO2007041569A1 (en) * 2005-09-30 2007-04-12 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
US8337824B2 (en) * 2008-08-22 2012-12-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions

Also Published As

Publication number Publication date
WO2005094384A3 (en) 2006-01-26
US20080241093A1 (en) 2008-10-02
KR20060135044A (ko) 2006-12-28
US20140286891A1 (en) 2014-09-25
US20130272991A1 (en) 2013-10-17
KR101228233B1 (ko) 2013-01-31
CA2557999C (en) 2013-11-12
WO2005097072A1 (en) 2005-10-20
CA2558029C (en) 2013-05-07
JP2007531726A (ja) 2007-11-08
WO2005094384A2 (en) 2005-10-13
BRPI0509365B8 (pt) 2021-05-25
CA2557848C (en) 2013-12-10
GB2430367A (en) 2007-03-28
US8778324B2 (en) 2014-07-15
EP1732516B1 (en) 2009-12-30
JP5000480B2 (ja) 2012-08-15
EP1732524B1 (en) 2012-08-22
CA2557848A1 (en) 2005-10-20
MXPA06011270A (es) 2007-03-08
PL1732523T3 (pl) 2010-08-31
BRPI0509366B1 (pt) 2018-07-24
GB2430368A (en) 2007-03-28
BRPI0509331A (pt) 2007-09-04
BRPI0509331B8 (pt) 2021-05-25
US8889115B2 (en) 2014-11-18
GB0621244D0 (en) 2006-12-13
EP1732524A4 (en) 2007-09-19
AU2005228696A1 (en) 2005-10-13
GB2430624A (en) 2007-04-04
GB0621242D0 (en) 2006-12-13
US8475780B2 (en) 2013-07-02
KR101153035B1 (ko) 2012-06-11
AU2005228696B2 (en) 2010-06-24
WO2005097081A1 (en) 2005-10-20
KR101199608B1 (ko) 2012-11-08
AU2005231424B2 (en) 2010-06-17
GB2430368B (en) 2009-08-26
US20130272992A1 (en) 2013-10-17
BRPI0509365A (pt) 2007-09-04
AU2005231424A1 (en) 2005-10-20
US20110206631A1 (en) 2011-08-25
US20130272990A1 (en) 2013-10-17
US20110033505A1 (en) 2011-02-10
KR20060135045A (ko) 2006-12-28
CA2558029A1 (en) 2005-10-20
GB2430624B (en) 2009-08-05
US10485821B2 (en) 2019-11-26
US8409561B2 (en) 2013-04-02
JP2007531758A (ja) 2007-11-08
US8287847B2 (en) 2012-10-16
US20080241092A1 (en) 2008-10-02
US20090148533A1 (en) 2009-06-11
EP1732524A2 (en) 2006-12-20
JP4964122B2 (ja) 2012-06-27
US20160317572A1 (en) 2016-11-03
US7776319B2 (en) 2010-08-17
GB0621241D0 (en) 2006-12-13
DE112005000730B4 (de) 2017-12-21
GB2430367B (en) 2009-08-05
BRPI0509366A (pt) 2007-09-04
BRPI0509365B1 (pt) 2018-06-12
US20060024265A1 (en) 2006-02-02
EP1732523B1 (en) 2010-03-17
JP2007531774A (ja) 2007-11-08
EP1732516A1 (en) 2006-12-20
US8282913B2 (en) 2012-10-09
US20080233073A1 (en) 2008-09-25
EP1732516A4 (en) 2007-06-06
CA2557999A1 (en) 2005-10-13
EP1732523A4 (en) 2007-06-06
US8445014B2 (en) 2013-05-21
US20200085856A1 (en) 2020-03-19
BRPI0509331B1 (pt) 2018-11-27
JP4974882B2 (ja) 2012-07-11
KR20070007168A (ko) 2007-01-12
AU2005231383B2 (en) 2010-06-10
US8216560B2 (en) 2012-07-10
US20160082039A1 (en) 2016-03-24
DE112005000730T5 (de) 2008-07-03
AU2005231383A1 (en) 2005-10-20
EP1732523A1 (en) 2006-12-20
EP1732523B9 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
BRPI0509366B8 (pt) composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica
GB2446076A (en) Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
WO2005092039A3 (en) Crosslinked amine polymers
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
BRPI0608249A2 (pt) formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
WO2010041268A3 (en) Crosslinked polymers
NO20054769L (no) Substituerte fenylalkansyrer
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
WO2009081408A3 (en) Pulverized fibrin clots and pharmaceutical compositions containing them
EP1938795A3 (en) Hair treatment composition, hair treatment agent and method for treating hair by using the same
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
BRPI0716066A2 (pt) composiÇço farmacÊutica, mÉtodo para tratar doenÇas, polÍmero de amina, rede polimÉrica, mÉtodo para preparar um polÍmero de amina, e, composto de amina
WO2006055725A3 (en) Substituted amino acids as protein tyrosine phosphatase inhibitors
DE602005020501D1 (de) Vernetzte aminpolymere
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
WO2007038801A3 (en) Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
WO2007056405A3 (en) Magnesium-containing polymers for the treatment of hyperphosphatemia
WO2005074887A3 (en) Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof
ATE453383T1 (de) Ionenbindende zusammensetzungen
ATE216247T1 (de) Aromatische oligomere verbindungen als imitatoren bioaktives makromoleküle
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
BRPI0508497A (pt) moduladores de canais de ìons e composição que os contém
WO2005030985A3 (en) Use of amino acid sequences involved in the elongation of fatty acids in identifying and/or developing compounds for preventing and/or treating metabolic diseases

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ILYPSA, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020120015935/RJ DE 27/02/2012.

B25G Requested change of headquarter approved

Owner name: ILYPSA, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020120016144/RJ DE 27/02/2012.

B25A Requested transfer of rights approved

Owner name: RELYPSA, INC. (US)

Free format text: TRANSFERIDO DE: ILYPSA, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved
B25C Requirement related to requested transfer of rights

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210065407 DE 19/07/2021, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA CESSIONARIA QUE CONSTA NA PROCURACAO E O NOME QUE APARECE NO DOCUMENTO DE CESSAO APRESENTADO. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2651 DE 26/10/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2873 DE 27/01/2026 POR TER SIDO INDEVIDA.